RT Journal Article
SR Electronic
T1 Trends in medication use after the onset of the COVID-19 pandemic in the Republic of Ireland: an interrupted time series study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.09.23291202
DO 10.1101/2023.06.09.23291202
A1 Mattsson, Molly
A1 Hong, Jung Ah
A1 Frazer, John Scott
A1 Frazer, Glenn Ross
A1 Moriarty, Frank
YR 2023
UL http://medrxiv.org/content/early/2023/06/12/2023.06.09.23291202.abstract
AB The COVID-19 pandemic had a substantial impact on healthcare delivery, particularly in general practice. This study aimed to evaluate how dispensing of medications in primary care in Ireland changed following the COVID-19 pandemic’s onset compared to expected trends. This interrupted time series study used data on medications prescribed in general practice 2016-2022 to patient eligible for state health cover, approximately one third of the population. Dispensing volumes for all therapeutic subgroups (ATC2 codes) and commonly dispensed medications were summarised. Pre-pandemic data was used to forecast expected trends (with 99% prediction intervals) using the Holt-Winters method, and these were compared to observed dispensing from March 2020 onwards. Most (31/77) therapeutic subgroups had dispensing significantly different from forecast in March 2020. Drugs for obstructive airway disease had the largest difference, with dispensing 26.2% (99%CI 19.5%-33.6%) higher than forecasted. Only two subgroups were significantly lower than forecasted, other gynaecologicals (17.7% lower, 99%CI 6.3%-26.6%) and dressings (11.6%, 99%CI 9.4%-41.6%). Dispensing of amoxicillin products and oral prednisolone were lower than forecasted in the months following the pandemic’s onset, particularly during winter 2020/2021. There was a spike in dispensing for many long-term medications in March 2020, while pandemic restrictions likely contributed to reductions for other medications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMM is supported by a grant from the Health Research Board under their Secondary Data Analysis Projects scheme (CDRx project, SDAP-2019-023, PI FM); JAH contributed to this research while on placement and was supported by funds from the School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available in Zenodo at https://doi.org/10.5281/zenodo.7999791. These data were derived from the Health Service Executive Primary Care Reimbursement Service's Reporting and Open Data platform available in the public domain: https://www.sspcrs.ie/portal/annual-reporting/ https://doi.org/10.5281/zenodo.7999791